Skip to main content

Compare Stocks

Date Range: 

 Intercept PharmaceuticalsBicycle TherapeuticsChimerixBELLUS HealthZIOPHARM Oncology
SymbolNASDAQ:ICPTNASDAQ:BCYCNASDAQ:CMRXOTCMKTS:BLUSFNASDAQ:ZIOP
Price Information
Current Price$18.15$31.18$8.20$3.64$3.17
52 Week RangeHoldBuyBuyN/AHold
MarketRank™
Overall Score2.21.31.70.51.3
Analysis Score4.13.54.50.03.2
Community Score3.12.42.42.52.4
Dividend Score0.00.00.00.00.0
Ownership Score3.30.81.70.00.8
Earnings & Valuation Score0.60.00.00.00.0
Analyst Ratings
Consensus RecommendationHoldBuyBuyN/AHold
Consensus Price Target$42.83$43.00$18.80N/A$5.63
% Upside from Price Target135.96% upside37.91% upside129.27% upsideN/A77.44% upside
Trade Information
Market Cap$601.89 million$749.19 million$706.93 million$579.19 million$683.21 million
Beta1.85-0.211.881.552.28
Average Volume1,135,132160,848992,89839,6102,460,786
Sales & Book Value
Annual Revenue$252 million$13.80 million$12.52 million$30,000.00$150,000.00
Price / Sales2.3954.2956.4619,306.204,554.76
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.57 per share$5.27 per share$1.79 per share$0.25 per share$0.52 per share
Price / Book11.565.924.5814.566.10
Profitability
Net Income$-344,680,000.00$-30,610,000.00$-112,580,000.00$-7,010,000.00$-117,800,000.00
EPS($10.89)($2.77)($0.86)N/A($0.34)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-106.64%-321.26%-321.31%-49,910.34%N/A
Return on Equity (ROE)-1,973.10%-42.73%-36.57%-48.37%-48.49%
Return on Assets (ROA)-48.51%-28.77%-33.53%-45.25%-43.53%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.13%N/AN/AN/A
Current Ratio3.44%9.63%12.18%13.87%10.12%
Quick Ratio3.44%9.63%12.18%13.87%10.12%
Ownership Information
Institutional Ownership Percentage85.77%42.68%45.41%N/A48.00%
Insider Ownership Percentage23.70%26.30%9.00%24.17%2.30%
Miscellaneous
Employees498875410103
Shares Outstanding33.16 million24.03 million86.21 million159.12 million215.53 million
Next Earnings Date8/9/2021 (Estimated)8/4/2021 (Estimated)8/9/2021 (Estimated)N/A8/5/2021 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Receives Average Rating of "Hold" from BrokeragesZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Receives Average Rating of "Hold" from Brokerages
americanbankingnews.com - May 16 at 2:44 AM
ZIOPHARM Oncology (NASDAQ:ZIOP) Given New $4.00 Price Target at Raymond JamesZIOPHARM Oncology (NASDAQ:ZIOP) Given New $4.00 Price Target at Raymond James
americanbankingnews.com - May 13 at 12:49 PM
ZIOPHARM Oncology (NASDAQ:ZIOP) Stock Price Up 2.3%ZIOPHARM Oncology (NASDAQ:ZIOP) Stock Price Up 2.3%
americanbankingnews.com - May 11 at 11:39 AM
ZIOPHARM Oncology (NASDAQ:ZIOP) Stock Rating Reaffirmed by HC WainwrightZIOPHARM Oncology (NASDAQ:ZIOP) Stock Rating Reaffirmed by HC Wainwright
americanbankingnews.com - May 10 at 8:36 AM
ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call PresentationZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 7 at 5:04 PM
ZIOPHARM Oncology (NASDAQ:ZIOP) Posts  Earnings Results, Beats Expectations By $0.01 EPSZIOPHARM Oncology (NASDAQ:ZIOP) Posts Earnings Results, Beats Expectations By $0.01 EPS
americanbankingnews.com - May 7 at 4:32 PM
ZIOPHARM Oncology Q1 Earnings PreviewZIOPHARM Oncology Q1 Earnings Preview
seekingalpha.com - May 7 at 1:00 PM
Ziopharm Oncology Inc (ZIOP) Q1 2021 Earnings Call TranscriptZiopharm Oncology Inc (ZIOP) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 7 at 1:00 PM
ZIOPHARM Oncology (NASDAQ:ZIOP) PT Lowered to $4.00ZIOPHARM Oncology (NASDAQ:ZIOP) PT Lowered to $4.00
americanbankingnews.com - May 7 at 9:46 AM
Ziopharm: Q1 Earnings SnapshotZiopharm: Q1 Earnings Snapshot
sfgate.com - May 6 at 7:13 PM
Ziopharm Oncology Reports First Quarter 2021 Financial Results and Provides Corporate UpdatesZiopharm Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Updates
finance.yahoo.com - May 6 at 7:13 PM
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Forecasted to Post FY2022 Earnings of ($0.48) Per ShareZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Forecasted to Post FY2022 Earnings of ($0.48) Per Share
americanbankingnews.com - May 6 at 10:01 AM
Ziopharm Oncology Scientific Advisor Laurence Cooper, MD, PhD, to Present at University of Pennsylvania Cellicon Valley ’21 Two-Day Live Virtual Educational SymposiumZiopharm Oncology Scientific Advisor Laurence Cooper, MD, PhD, to Present at University of Pennsylvania Cellicon Valley ’21 Two-Day Live Virtual Educational Symposium
finance.yahoo.com - May 4 at 10:17 AM
Zacks: Analysts Anticipate ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Will Announce Earnings of -$0.11 Per ShareZacks: Analysts Anticipate ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Will Announce Earnings of -$0.11 Per Share
americanbankingnews.com - May 1 at 6:20 PM
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP): How Much Is It Worth And What Should Investors Do?ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP): How Much Is It Worth And What Should Investors Do?
marketingsentinel.com - April 30 at 1:04 PM
ZIOPHARM Oncology (ZIOP) Set to Announce Earnings on ThursdayZIOPHARM Oncology (ZIOP) Set to Announce Earnings on Thursday
americanbankingnews.com - April 30 at 10:56 AM
Ziopharm Oncology to Report First Quarter Financial Results on May 6, 2021Ziopharm Oncology to Report First Quarter Financial Results on May 6, 2021
finance.yahoo.com - April 29 at 12:00 PM
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Stock Forecast 2021: $7.5 Per Share With Bullish SignsZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Stock Forecast 2021: $7.5 Per Share With Bullish Signs
marketingsentinel.com - April 27 at 12:45 PM
Analysts believe ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)’s share price will rise 127.27% from current levelsAnalysts believe ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)’s share price will rise 127.27% from current levels
stocksregister.com - April 26 at 8:53 AM
ZIOPHARM Oncology (NASDAQ:ZIOP) Stock Price Down 4.2%ZIOPHARM Oncology (NASDAQ:ZIOP) Stock Price Down 4.2%
americanbankingnews.com - April 22 at 12:50 PM
Cedilla Therapeutics Appoints Chris Bowden, M.D. to its Board of DirectorsCedilla Therapeutics Appoints Chris Bowden, M.D. to its Board of Directors
ca.finance.yahoo.com - April 21 at 12:42 PM
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Given Consensus Rating of "Hold" by AnalystsZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Given Consensus Rating of "Hold" by Analysts
americanbankingnews.com - April 21 at 2:30 AM
Ziopharm Oncology buy DomRuinartZiopharm Oncology buy DomRuinart
sharewise.com - April 19 at 8:24 AM
Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCellZiopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell
finance.yahoo.com - April 19 at 8:24 AM
Will current price volatility hamper ZIOPHARM Oncology, Inc. (ZIOP) future potential?Will current price volatility hamper ZIOPHARM Oncology, Inc. (ZIOP) future potential?
marketingsentinel.com - April 13 at 12:26 PM
DateCompanyBrokerageAction
5/13/2021Intercept PharmaceuticalsRaymond JamesLower Price Target
5/13/2021Intercept PharmaceuticalsThe Goldman Sachs GroupLower Price Target
5/10/2021Intercept PharmaceuticalsOppenheimerLower Price Target
5/7/2021Intercept PharmaceuticalsBMO Capital MarketsLower Price Target
5/7/2021Intercept PharmaceuticalsCantor FitzgeraldLower Price Target
5/6/2021Intercept PharmaceuticalsStifel NicolausLower Price Target
3/18/2021Intercept PharmaceuticalsHC WainwrightUpgrade
3/8/2021Intercept PharmaceuticalsWedbushLower Price Target
3/8/2021Intercept PharmaceuticalsNeedham & Company LLCLower Price Target
3/1/2021Intercept PharmaceuticalsB. RileyLower Price Target
3/1/2021Intercept PharmaceuticalsChardan CapitalLower Price Target
1/15/2021Intercept PharmaceuticalsBank of AmericaDowngrade
12/21/2020Intercept PharmaceuticalsJefferies Financial GroupDowngrade
11/11/2020Intercept PharmaceuticalsCanaccord GenuityBoost Price Target
5/7/2021Bicycle TherapeuticsPiper SandlerBoost Price Target
4/26/2021Bicycle TherapeuticsJMP SecuritiesInitiated Coverage
11/14/2019Bicycle TherapeuticsRoth CapitalInitiated Coverage
5/5/2021ChimerixMaxim GroupInitiated Coverage
4/12/2021ChimerixJonestradingReiterated Rating
5/9/2019ChimerixCowenReiterated Rating
3/6/2019ChimerixCitigroupLower Price Target
6/21/2020ZIOPHARM OncologyLaidlawReiterated Rating
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.